• ActivX Biosciences Inc., of La Jolla, Calif., a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co. Ltd., filed an investigational new drug application with the FDA for KRP-104, a therapy targeting Type II diabetes. The Phase I trial with KRP-104 began March 3.

• Generex Biotechnology Corp., of Toronto, disclosed more preliminary results (10 weeks) of a long-term (six month) trial of Generex Oral-lyn, the company’s oral insulin spray, in adolescent and young adult patients with Type I diabetes. The data, which complement the positive results disclosed March 8, show the variations of glycosylated hemoglobin, a well-known marker for monitoring diabetes, during the first 10 weeks of the study.

No Comments